Dr. Brian J. Heller, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 464
Licensed in Alabama since 2007, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Louisiana State University School of Medicine in New Orleans
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
AL license 28155 (first issued 2007; active) -
Hematology & Oncology Physician
AL license 00028155 · LA license 023686
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mobile Infirmary Medical Center Mobile, AL
- USA Health HCA Providence Hospital, LLC Mobile, AL
- Springhill Medical Center Mobile, AL
Medical groups
- Southern Cancer Center PC (25 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 464
- Services billed
- 152,285
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 33,800 | 26 |
| Injection, nivolumab, 1 mg | 22,920 | 11 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 19,890 | 24 |
| Injection, fosaprepitant, 1 mg | 18,300 | 33 |
| Injection, denosumab, 1 mg | 2,700 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,880 | 54 |
| Injection, palonosetron hcl, 25 mcg | 1,420 | 41 |
| Insertion of needle into vein for collection of blood sample | 799 | 305 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 776 | 303 |
| Injection, ondansetron hydrochloride, per 1 mg | 768 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Exemestane | 294 |
| Letrozole Other prescribers in Mobile, AL | 172 |
| Ondansetron Hcl Other prescribers in Mobile, AL | 128 |
| Prochlorperazine Maleate Other prescribers in Mobile, AL | 84 |
| Amlodipine Besylate Other prescribers in Mobile, AL | 74 |
| Levothyroxine Sodium Other prescribers in Mobile, AL | 70 |
| Potassium Chloride Other prescribers in Mobile, AL | 67 |
| Dexamethasone Other prescribers in Mobile, AL | 67 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Mobile, AL | 64 |
| Eliquis (apixaban) Other prescribers in Mobile, AL | 60 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 46 payments worth $1,220 in total to this clinician.
| Merck Sharp & Dohme LLC | $158 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $125 |
| Ipsen Biopharmaceuticals, Inc | $116 |
| Beone Medicines USA, Inc. | $95.55 |
| Daiichi Sankyo Inc. | $92.46 |
| GlaxoSmithKline, LLC. | $60.03 |
| Gilead Sciences, Inc. | $56.14 |
| Novartis Pharmaceuticals Corporation | $52.30 |
| Food and Beverage | $1,220 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $8,326 in research payments for these studies, mostly to the institutions running them.
- Pallaspalbociclib collaborative adjuvant studya randomized phase iii trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hr or HER2 early breast cancer WI…
Pfizer Inc. - Brightline-2 PhIIa/IIb Brigimadlin mono in MDM2 amp tumors
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.